Dr. Moskowitz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1120 NW 14th St
Don Soffer Clinical Research Center, 660E
Miami, FL 33136- Is this information wrong?
Summary
- Dr. Craig Moskowitz is an oncologist in Miami, FL and is affiliated with multiple hospitals in the area, including Memorial Sloan-Kettering Cancer Center, NYC Health + Hospitals / Bellevue, and University of Miami Hospital and Clinics. He received his medical degree from Wayne State University School of Medicine and has been in practice 29 years. He specializes in hematologic oncology and is experienced in hematologic oncology, diffuse large b-cell lymphoma, hodgkin's lymphoma, hodgkin disease, and mantle cell.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1988 - 1992
Wayne State University School of MedicineClass of 1988
Certifications & Licensure
FL State Medical License 2018 - 2026
NY State Medical License 1989 - 2026- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2012-2014
- Super Doctor SuperDoctors.com
Clinical Trials
- Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma Start of enrollment: 1995 Sep 01
- Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma Start of enrollment: 1997 Jan 01
- Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma Start of enrollment: 1999 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Brentuximab Vedotin and Chemotherapy in Relapsed/Refractory Hodgkin Lymphoma: a Propensity Score Matched Analysis.Julia Driessen, Fer de Wit, Alex F Herrera, Pier Luigi Zinzani, Ann S LaCasce, Peter D Cole, Craig H Moskowitz, Ramón García-Sanz, Michael Fuchs, Horst Mueller, Peter ...> ;Blood Advances. 2024 Mar 19
- Matched control analysis suggests R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared to R-CHOP.Bantilan, K., Smith, A., Maurer, M., Teruya-Feldstein, J., Matasar, M., Moskowitz, A., Straus, D., Noy, A., Palomba, M., Horwitz, S., Hamlin, P., Portlock, C., Cerhan,...> ;Blood Advances. 2024 Jan 25
- PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.Alderuccio, J., Reis, I., Hamadani, M., Nachiappan, M., Leslom, S., Kahl, B., Ai, W., Radford, J., Solh, M., Ardeshna, K., Hess, B., Lunning, M., Zinzani, P., Stathis,...> ;Clinical Cancer Research. 2024 Jan 5
- Join now to see all
Journal Articles
- Five-Year PFS from the AETHERA Trial of Brentuximab Vedotin for Hodgkin Lymphoma at High Risk of Progression or RelapsePatrick Stiff, Edward Agura, Craig H Moskowitz, John Sweetenham, Auayporn Nademanee, Veronika Bachanova, Blood
- CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PETDavid J Straus, Heiko Schoder, Bruce D Cheson, John C Grecula, Lale Kostakoglu, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonath..., Blood
Lectures
- Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Survival for Relapsed/Refractory Hodgkin Lymphoma Patients with Recurrent or Persistent Disease Following Autologous Hematopoietic Stem Cell Transplantation Treated in...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Dedicated Neuroendocrine Tumors Program Launched at Sylvester Comprehensive Cancer CenterMarch 16th, 2023- Study: Whole Genome Sequencing Provides Unprecedented Detail on the Genetic Evolution of Hodgkin LymphomaFebruary 21st, 2023
- Sylvester Pursues Landmark Research Presented at International Hematology ConferenceJanuary 30th, 2023
- Join now to see all
Hospital Affiliations
UMHC-Sylvester Comprehensive Cancer CenterMiami, Florida
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
